Mechanism of Action (MOA) Studies and Cell-Based Assays at Our 20+ Year, FDA-Inspected Lab

It is the study that turns my molecule works into my molecule works because. MOA studies demonstrate, inside living cells, that your compound engages its intended target, that the downstream pathway actually moves, and that the effect belongs to the target rather than to an off-target accident. Investors, partners and reviewers all eventually ask the same question; the MOA package is the prepared answer.

Five pillars, roughly: target engagement in a living cell, pathway movement shown by reporter or expression readouts, genetic confirmation where removing the target removes the effect, dose dependence across a full curve, and demonstration in a disease-relevant cell type, human where the translational question is real. One assay proves none of it; the package is the proof.

Either. Transient transfection or a stable line can be built here to carry your target in relevant biology, qualified and banked for reuse. If you already have the model, send it with its history and we qualify it into the assay. The choice is scoped honestly: building a stable line costs time upfront and repays it in reproducibility across a program.

By proximity-based readouts such as BRET and FRET, which report your molecule at its target in a living cell rather than in a tube. Engagement measured against purified protein is a biochemical answer; programs defending a cellular mechanism need the cellular measurement, and the two together are stronger than either.

Because it is the cleanest logic in the package: remove the target by knockdown or siRNA, and the compound’s effect should disappear. If it does not, the effect lives somewhere else, and that is worth knowing before the mechanism story ships. We treat genetic confirmation as standard rather than optional, since a mechanism that survives it is a mechanism worth defending.

Counter-screens and selectivity work run in cells, so the observed effect gets attributed correctly. Dose-response symmetry between target engagement and phenotype, rescue and knockdown logic, and related-target panels each close a door an off-target explanation could walk through. The claim that survives is smaller and much harder to attack.

The pathway decides. Transcriptional mechanisms read cleanly by reporter constructs and by qPCR or ddPCR at the transcript level; signaling mechanisms show in phosphorylation by western blot; localization and morphology belong to imaging. Most packages combine two, one functional and one molecular, because agreement between independent readouts is what makes a mechanism persuasive.

Then we say so plainly. Some mechanisms need the purified target and a biochemical answer, and some questions need an unbiased screen rather than a hypothesis test. Both routes exist under this roof, so the honest answer costs you a conversation, not a vendor change.